ASCO 2021 Bladder Cancer - Results from #20

Viewing 21-38 of 38 articles

ASCO 2021: Practical Considerations for the Treatment of Patients on Long-term Immunotherapy

ASCO 2021: Pembrolizumab Versus Investigator’s Choice of Paclitaxel, Docetaxel, or Vinflunine in Recurrent, Advanced Urothelial Cancer: 5-Year Follow-up from the Phase 3 KEYNOTE-045 Trial

ASCO 2021: Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase 2 Trial

ASCO 2021: A Phase 3, Multicenter, Randomized Study Evaluating the Efficacy of TAR-200 in Combination with Cetrelimab Versus Concurrent Chemoradiotherapy in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder

ASCO 2021: PrE0807: A Phase Ib Feasibility Trial of Neoadjuvant Nivolumab Without or with Lirilumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer

ASCO 2021: Older, Wiser, and Better: Clinical Trial Enrollment and Optimal Care for Older Adults with Kidney and Bladder Cancer

ASCO 2021: Women and Bladder Cancer: Ensuring the Best Care for All of Our Patients

ASCO 2021: Regulating Change: The FDA and Diversity in the Modern Era of Genitourinary Oncology Trials

ASCO 2021: Novel Immunotherapy Approaches Across the Spectrum of Urothelial Cancer Stages

ASCO 2021: Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605

ASCO 2021: KEYNOTE-B15/EV-304: Randomized Phase 3 Study of Perioperative Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

ASCO 2021: Quality of Life, Functioning, and Symptoms in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma from EV-301: A Randomized Phase 3 Trial of Enfortumab Vedotin vs Chemotherapy

ASCO 2021: Impact of Recurrence On Health-Related Quality of Life In Patients at High Risk of Recurrence After Radical Surgery For Muscle-Invasive Urothelial Carcinoma: Results From the Phase 3 CheckMate 274 Trial

ASCO 2021: Study EV-103: Update on Durability Results and Long Term Outcome of Enfortumab Vedotin + Pembrolizumab in First Line Locally Advanced or Metastatic Urothelial Carcinoma

ASCO 2021: Enfortumab Vedotin in Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer Who Received Prior PD-1/PD-L1 Inhibitors: An Updated Analysis of EV-201 Cohort 2

ASCO 2021: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma in the JAVELIN Bladder 100 Trial: Subgroup Analysis by Duration of Treatment-Free Interval from End of Chemotherapy to Start of Maintenance

ASCO 2021: Avelumab First-Line Maintenance plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma: Analysis of Time to End of Next-Line Therapy in JAVELIN Bladder 100

ASCO 2021: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Analysis of Clinical and Genomic Subgroups from the JAVELIN Bladder 100 Trial

1
2